Alterations to the respiratory microbiome have been identified as a predisposing factor of interstitial lung diseases (ILD). In a new study, researchers studied the influence of bacterial virulence on clinical outcomes patients hospitalized with ILD patients. The authors found that the use of immunosuppressive medications or antifibrotics had no influence on the outcomes including development of resistant pathogens in patients.